Medical experts have renamed polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS) to better encompass the condition's wide-ranging effects on multiple body systems, which extend beyond fertility and ovarian function.
The change aims to address decades of confusion caused by the previous name, which experts say did not accurately reflect the complex hormonal and metabolic disorder experienced by patients.
PMOS affects approximately one in eight women of reproductive age worldwide. Its varied presentation and overlapping symptoms with common adolescent changes, such as acne and irregular periods, often contribute to delayed or missed diagnoses. Furthermore, hormonal birth control can mask symptoms, leading individuals to discover the condition only when they stop using it, often when trying to conceive.
"Because medical terminology shapes how both patients and providers understand disease, the old name may have contributed to delayed diagnoses, oversimplified the condition and left many women feeling misunderstood," according to the report.
Diagnosis of PMOS relies on a combination of symptoms and clinical findings, as there is no single definitive test. This diagnostic complexity, particularly for healthcare providers not specializing in the condition, can lead to prolonged periods of unanswered questions for patients.
Misconceptions about PMOS persist, including the belief that it is defined by ovarian cysts. The structures often observed on ovaries are immature follicles, not true cysts, making the former name misleading. Another myth is that only overweight individuals develop PMOS; lean individuals also experience symptoms, a presentation known as lean PMOS.
Contrary to popular belief, PMOS is not caused by poor lifestyle habits or overeating. It is a complex polygenic disorder often influenced by genetics, though healthy eating and exercise can help manage symptoms.
Beyond reproductive health, PMOS is associated with increased risks of cardiovascular disease, Type 2 diabetes, insulin resistance, sleep apnea, and gastrointestinal issues. Mental health is also significantly impacted, with higher rates of anxiety and depression reported among those with the condition.
Treatment for PMOS is highly individualized, tailored to each patient's specific concerns and life stage. Approaches can include medications to manage androgen levels for acne and hair growth, drugs like metformin or GLP-1s for insulin resistance and weight management, hormonal treatments for irregular periods, and fertility treatments such as letrozole, clomiphene, or in vitro fertilization (IVF).
Experts advise individuals experiencing symptoms like irregular periods, persistent acne, excess facial or body hair, or unexplained weight resistance to seek medical advice. Given the condition's multi-systemic nature, care may involve a team of specialists, including primary care physicians, OB-GYNs, reproductive endocrinologists, and dermatologists.
Early diagnosis and ongoing monitoring are crucial for managing PMOS, a lifelong condition that can continue to pose metabolic and hormonal risks even after menopause. Regular checkups and screenings for cardiovascular risk factors can help prevent serious complications.